Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Somatuline
| Field | Information |
|---|---|
| Medication Name | Somatuline |
| Generic Name | Lanreotide |
| Boxed/Label Warning | May cause gallbladder abnormalities, including cholelithiasis (gallstones) and cholecystitis. Monitor for signs and symptoms. |
| Purpose | Treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Mechanism of Action | Synthetic somatostatin analog that inhibits the secretion of growth hormone and other hormones |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 60 mg, 90 mg, 120 mg |
| Dosage Frequency | Every 28 days (4 weeks) or every 14 days (2 weeks), depending on the condition and response |
| Common Side Effects | Injection site reactions (pain, nodules), diarrhea, abdominal pain, nausea, vomiting, fatigue |
| Serious Side Effects | Gallbladder abnormalities (gallstones, cholecystitis), bradycardia (slow heart rate), hyperglycemia (high blood sugar), hypoglycemia (low blood sugar), thyroid abnormalities |
| Drug Interactions | Cyclosporine, bromocriptine, insulin, oral hypoglycemic agents, beta-blockers, quinidine |
| Important Notes | Monitor blood glucose levels, thyroid function, and gallbladder status during treatment. Notify your doctor if you experience severe abdominal pain, jaundice, or changes in heart rate. |
| Storage | Store refrigerated at 2-8°C (36-46°F). Protect from light. |
| Missed Dose | Contact your healthcare provider immediately to reschedule the injection as soon as possible. Do not administer a double dose. |
| Alternatives | Octreotide, Pasireotide, Pegvisomant |
Somatuline Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Octreotide (Sandostatin) | Synthetic somatostatin analog | Available as a subcutaneous injection or intravenous infusion. Used to treat acromegaly and certain neuroendocrine tumors. |
| Pasireotide (Signifor) | Somatostatin analog with broader receptor binding | Subcutaneous injection used to treat Cushing’s disease and acromegaly in patients not adequately controlled on other somatostatin analogs. |
| Pegvisomant (Somavert) | Growth hormone receptor antagonist | Subcutaneous injection used to treat acromegaly by blocking the effects of growth hormone. |
Somatuline Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Injection site reactions (pain, nodules) | Gallbladder abnormalities (gallstones, cholecystitis) |
| Diarrhea | Bradycardia (slow heart rate) |
| Abdominal pain | Hyperglycemia (high blood sugar) |
| Nausea | Hypoglycemia (low blood sugar) |
| Vomiting | Thyroid abnormalities |
| Fatigue | Cardiac arrhythmias |
Somatuline Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Acromegaly | 90 mg every 4 weeks | 60-120 mg every 4 weeks, adjust based on GH and IGF-1 levels | Administer via deep subcutaneous injection. Rotate injection sites. |
| GEP-NETs | 120 mg every 4 weeks | 120 mg every 4 weeks, may be adjusted based on individual response | Administer via deep subcutaneous injection. Rotate injection sites. |
Somatuline Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $50 |
| Without Insurance (U.S.) | $5,653 |
| From CPS | $2,557 |
